Milestone Pharmaceuticals Secures FDA Approval for CARDAMYST, Boosts Liquidity with $75M Royalty Sale and Public Offering

summarizeSummary

Milestone Pharmaceuticals reported its annual results, highlighting the FDA approval of CARDAMYST for PSVT, a $75 million royalty sale, and a $48.6 million public offering to fund commercialization and pipeline development, despite increased net losses.

check_boxKey Events

• FDA Approval of CARDAMYST

  The company received FDA approval for CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT) on December 12, 2025, with commercialization commencing in Q1 2026.

• $75 Million Royalty Sale

  Subsequent to the fiscal year end, on January 12, 2026, Milestone Pharmaceuticals closed a royalty purchase agreement, receiving $75.0 million from RTW for tiered quarterly royalty payments on U.S. net product sales of CARDAMYST.

• $48.6 Million Public Offering

  In July 2025, the company completed an underwritten public offering, raising $48.6 million in net proceeds from the sale of common shares, Series A and B common warrants, and pre-funded warrants.

• Increased Net Loss

  The net loss for the year ended December 31, 2025, increased to $63.1 million from $41.5 million in 2024, primarily due to increased commercial expenses related to the CARDAMYST launch.

auto_awesomeAnalysis

The FDA approval of CARDAMYST for PSVT on December 12, 2025, is a transformative event for Milestone Pharmaceuticals, enabling commercialization which commenced in Q1 2026. This significant regulatory milestone is bolstered by substantial financing activities, including a $75 million royalty sale (closed in January 2026) and a $48.6 million public offering in July 2025, providing critical capital for the launch and pipeline advancement. The company also reported a notable increase in net loss to $63.1 million in 2025, primarily due to investments in commercialization infrastructure. Despite these losses, management projects sufficient liquidity for the next 12 months, and progress continues on the Phase 3 development of etripamil for AFib-RVR, guided by positive FDA feedback. Investors should monitor the commercial uptake of CARDAMYST and further pipeline developments, as the company balances growth initiatives with ongoing capital requirements.